Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective - PubMed (original) (raw)

Review

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective

Shahneen K Sandhu et al. Eur J Cancer. 2010 Jan.

Abstract

Inbuilt mechanisms of DNA surveillance and repair are integral to the maintenance of genomic stability. Poly(ADP-ribose) polymerase (PARP) is a nuclear enzyme that plays a critical role in DNA damage response processes. PARP inhibition has been successfully employed as a novel therapeutic strategy to enhance the cytotoxic effects of DNA-damaging agents. We have shown that PARP inhibition has substantial single agent antitumour activity with a wide therapeutic index in homologous DNA repair-defective tumours such as those arising in BRCA1 and BRCA2 mutation carriers. This is the first successful clinical application of a synthetic lethal approach to targeting cancer. Exploitation of defects in DNA repair pathways through targeted inhibition of salvage repair pathways is an exciting anticancer approach, with potentially broad clinical applicability. Several PARP inhibitors are now in clinical development. This review outlines the biological function and rationale of targeting PARP, details pre-clinical and clinical data and discusses the promises and challenges involved in developing these antitumour agents.

PubMed Disclaimer

Similar articles

• Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
  Yap TA, Sandhu SK, Carden CP, de Bono JS. Yap TA, et al. CA Cancer J Clin. 2011 Jan-Feb;61(1):31-49. doi: 10.3322/caac.20095. Epub 2011 Jan 4. CA Cancer J Clin. 2011. PMID: 21205831 Review.
• The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.
  Sandhu SK, Yap TA, de Bono JS. Sandhu SK, et al. Curr Drug Targets. 2011 Dec;12(14):2034-44. doi: 10.2174/138945011798829438. Curr Drug Targets. 2011. PMID: 21777194 Review.
• Targeting the DNA damage response in oncology: past, present and future perspectives.
  Basu B, Yap TA, Molife LR, de Bono JS. Basu B, et al. Curr Opin Oncol. 2012 May;24(3):316-24. doi: 10.1097/CCO.0b013e32835280c6. Curr Opin Oncol. 2012. PMID: 22476188 Review.
• PARP inhibitors for cancer therapy.
  Curtin NJ. Curtin NJ. Expert Rev Mol Med. 2005 Mar 15;7(4):1-20. doi: 10.1017/S146239940500904X. Expert Rev Mol Med. 2005. PMID: 15836799 Review.
• Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
  Heitz F, Harter P, Ewald-Riegler N, Papsdorf M, Kommoss S, du Bois A. Heitz F, et al. Expert Rev Anticancer Ther. 2010 Jul;10(7):1125-36. doi: 10.1586/era.10.53. Expert Rev Anticancer Ther. 2010. PMID: 20645701 Review.

Cited by

• Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models.
  Mansur A, Song PN, Lu Y, Burns AC, Sligh L, Yang ES, Sorace AG. Mansur A, et al. Biomedicines. 2023 Jul 25;11(8):2090. doi: 10.3390/biomedicines11082090. Biomedicines. 2023. PMID: 37626587 Free PMC article.
• PARP Inhibitors: Clinical Limitations and Recent Attempts to Overcome Them.
  Kim D, Nam HJ. Kim D, et al. Int J Mol Sci. 2022 Jul 29;23(15):8412. doi: 10.3390/ijms23158412. Int J Mol Sci. 2022. PMID: 35955544 Free PMC article. Review.
• Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation.
  Césaire M, Ghosh U, Austry JB, Muller E, Cammarata FP, Guillamin M, Caruso M, Castéra L, Petringa G, Cirrone GAP, Chevalier F. Césaire M, et al. J Bone Oncol. 2019 Jun 20;17:100246. doi: 10.1016/j.jbo.2019.100246. eCollection 2019 Aug. J Bone Oncol. 2019. PMID: 31312595 Free PMC article.
• Potential role of poly (ADP-ribose) polymerase in delayed cerebral vasospasm following subarachnoid hemorrhage in rats.
  Fan Y, Yan G, Liu F, Rong J, Ma W, Yang D, Yu Y. Fan Y, et al. Exp Ther Med. 2019 Feb;17(2):1290-1299. doi: 10.3892/etm.2018.7073. Epub 2018 Dec 7. Exp Ther Med. 2019. PMID: 30680005 Free PMC article.
• Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
  O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP. O'Reilly EM, et al. Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16. Cancer. 2018. PMID: 29338080 Free PMC article. Clinical Trial.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations

• Miscellaneous

  • NCI CPTAC Assay Portal